31 related articles for article (PubMed ID: 15569989)
1. Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy.
Santos JG; Faria G; Cruz WDCSD; Fontes CA; Schönthal AH; Quirico-Santos T; da Fonseca CO
Surg Neurol Int; 2020; 11():389. PubMed ID: 33282452
[TBL] [Abstract][Full Text] [Related]
2. Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker.
Cohen AL; Neumayer L; Boucher K; Factor RE; Shrestha G; Wade M; Lamb JG; Arbogast K; Piccolo SR; Riegert J; Schabel M; Bild AH; Werner TL
JCO Precis Oncol; 2017; 1():. PubMed ID: 32913974
[TBL] [Abstract][Full Text] [Related]
3. Predictors of willingness to participate in window-of-opportunity breast trials.
Wisinski KB; Faerber A; Wagner S; Havighurst TC; McElroy JA; Kim K; Bailey HH
Clin Med Res; 2013 Sep; 11(3):107-12. PubMed ID: 23580787
[TBL] [Abstract][Full Text] [Related]
4. Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.
de Saldanha da Gama Fischer J; Costa Carvalho P; da Fonseca CO; Liao L; Degrave WM; da Gloria da Costa Carvalho M; Yates JR; Domont GB
J Proteome Res; 2011 Jan; 10(1):153-60. PubMed ID: 20806975
[TBL] [Abstract][Full Text] [Related]
5. Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol.
Fischer Jde S; Liao L; Carvalho PC; Barbosa VC; Domont GB; Carvalho Mda G; Yates JR
J Proteomics; 2010 Mar; 73(5):1018-27. PubMed ID: 20083244
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms involved in farnesol-induced apoptosis.
Joo JH; Jetten AM
Cancer Lett; 2010 Jan; 287(2):123-35. PubMed ID: 19520495
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
8. A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer.
Dhingra K
J Cell Biochem Suppl; 1995; 23():19-24. PubMed ID: 8747374
[TBL] [Abstract][Full Text] [Related]
9. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
Stearns V; Coop A; Singh B; Gallagher A; Yamauchi H; Lieberman R; Pennanen M; Trock B; Hayes DF; Ellis MJ
Clin Cancer Res; 2004 Nov; 10(22):7583-91. PubMed ID: 15569989
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
Bailey HH; Attia S; Love RR; Fass T; Chappell R; Tutsch K; Harris L; Jumonville A; Hansen R; Shapiro GR; Stewart JA
Cancer Chemother Pharmacol; 2008 Jun; 62(1):149-57. PubMed ID: 17885756
[TBL] [Abstract][Full Text] [Related]
11. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide.
Singletary E; Lieberman R; Atkinson N; Sneige N; Sahin A; Tolley S; Colchin M; Bevers T; Stelling C; Fornage B; Fritsche H; Hittelman W; Kelloff G; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1087-90. PubMed ID: 11045792
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.
Singh B; Smith JA; Axelrod DM; Ameri P; Levitt H; Danoff A; Lesser M; de Angelis C; Illa-Bochaca I; Lubitz S; Huberman D; Darvishian F; Kleinberg DL
Breast Cancer Res; 2014 Nov; 16(6):463. PubMed ID: 25385439
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
